AcquisitionsSvas Biosana expands its presence in Serbia by integrating Hermes Pharma and Megapharm, two distributors specialising in cardiology and neuro-cardiology.
Analyst RecommendationAnalyst maintains a Buy recommendation with a target price of €12.4.
EarningsSvas Biosana delivered a solid 1Q 2025 with revenues of €32.7m (+14.3% YoY, +6.6% standalone), driven by recent acquisitions and strong momentum in the Balkans.